hotspot -WSS

hotspot

author：Wikipedia 2025-08-12 06:42:10 - browse：5

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Achieving telehealth equity for people with hearing loss

WSS

Congress: Prevent baby formula shortages by passing a new bill

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Lawsuit challenges CMS nursing home minimum staffing rule

How dance can help nurses traumatized by Covid

Why hospitals are withdrawing from US News rankings

Sanofi seeks simpler, safer CRISPR sickle cell cure

hotspot

hotspot

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Listen: Wegovy in the brain & pivotal Alzheimer's data

Hepatitis C has a cure — but many Americans still lack access to it

Congress: Prevent baby formula shortages by passing a new bill

Medicare details structure of new drug price negotiation program

Startup Neumora takes a novel depression drug to Phase 3

Anesthesiologist group: stop taking Ozempic before surgery

Achieving telehealth equity for people with hearing loss

Duchenne breakthrough therapy leaves behind pioneering families

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

explore

Louisiana bill approved classifying abortion pills as controlled substances

Cosmetics set for new safety regulation. Why the industry is on board

Why we need mandatory labeling of GMO products

Achieving telehealth equity for people with hearing loss

Ozempic cut risk of death in diabetes patients with chronic kidney disease

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

hotspot

leisure time

explore

hotspot